Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Accured Expenses (2016 - 2025)

Ptc Therapeutics has reported Change in Accured Expenses over the past 14 years, most recently at $18.9 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $18.9 million for Q4 2025, up 14.38% from a year ago — trailing twelve months through Dec 2025 was -$17.4 million (down 247.05% YoY), and the annual figure for FY2025 was -$17.4 million, down 247.05%.
  • Change in Accured Expenses for Q4 2025 was $18.9 million at Ptc Therapeutics, up from -$19.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PTCT hit a ceiling of $43.5 million in Q3 2023 and a floor of -$42.7 million in Q4 2023.
  • Median Change in Accured Expenses over the past 5 years was -$1.8 million (2021), compared with a mean of -$956750.0.
  • Biggest five-year swings in Change in Accured Expenses: soared 11013.85% in 2021 and later plummeted 1526.9% in 2024.
  • Ptc Therapeutics' Change in Accured Expenses stood at -$2.4 million in 2021, then crashed by 54.4% to -$3.6 million in 2022, then tumbled by 1070.99% to -$42.7 million in 2023, then skyrocketed by 138.75% to $16.6 million in 2024, then increased by 14.38% to $18.9 million in 2025.
  • The last three reported values for Change in Accured Expenses were $18.9 million (Q4 2025), -$19.0 million (Q3 2025), and -$35.8 million (Q2 2025) per Business Quant data.